Mechanisms of action of glucagon-like peptide 1 in the pancreas.

By M. Doyle, J. Egan. Pharmacology and Therapeutics, 2007

670 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/0ec1beaadac16a190e0456bbf53ec2fe05a631fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Josephine M. Egan
2. Wook Kim
3. M. Nauck
4. D. J. Drucker
5. F. Reimann
6. E. Gilbert
7. Zhuo Fu
8. Dongmin Liu

In Molecular Biology

1. M. Nauck
2. E. Gilbert
3. Zhuo Fu
4. Josephine M. Egan
5. Wook Kim
6. Dongmin Liu
7. D. J. Drucker

In Surgery

1. M. Nauck
2. Josephine M. Egan
3. Wook Kim
4. D. J. Drucker
5. F. Reimann
6. E. Gilbert
7. Zhuo Fu
8. Dongmin Liu

Citations in the corpus

• Glucagon-like peptide 1 (GLP-1) (2019, background): “Underlining the role of the KATP channels in mediating this process, glucose-stimulated Ca2þ entry and GLP-1 secretion are mimicked upon treatment of GLUTag cells with the KATP channel inhibitor tolbutamide [265].”
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Glucagon, for example, binds GLP-1R with 100- to 1000-fold less affinity than does GLP-1 (Thorens, 1992; Fehmann et al., 1994; Doyle and Egan, 2007).”
• Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes (2012, positive): “Upon activation of the GLP-1 receptor (GLP-1R), adenylyl cyclase is activated, leading to the generation of cAMP [246].”